DNA / Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now

Ginkgo Bioworks is analyzed based on Porter's Five Forces framework for competitive dynamics. The threat of competition in Ginkgo's R&D discovery busi more_horizontal

Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, but th more_horizontal

Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia more_horizontal

While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and more_horizontal

Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make more_horizontal

Growth stocks are an important element of a well-balanced portfolio. Ginkgo Bioworks and Harmony Biosciences are two risky growth plays that could del more_horizontal

Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy reve more_horizontal

Ginkgo Bioworks and Pfizer announced a new RNA therapeutics collaboration today. In response, Ginkgo Bioworks' stock jumped by double digits in early- more_horizontal